In addition to sequencing results supporting JAK/STAT amplification in CTCL, JAKis have been administered to several CTCL patients as detailed in a few published case reports and clinical trials. Here, SOAT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.